EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Chronic Myeloid Leukemia and the T315I BCR::ABL1 Mutation

Federico Pierro, Stefania Stella, Manlio Fazio iD, Sabina Russo, Michele Massimino iD, Giuseppe Mirabile, Daniela Belletti, Alessandro Allegra iD, Fabio Stagno iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms262311285 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Federico Pierro und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Human Pathology in Adulthood and Childhood "Gaetano Barresi", University of Messina, Via Consolare Valeria, 981…. Hauptthemen laut MEDLINE: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Fusion Proteins, bcr-abl, Mutation, Proto-Oncogene Proteins c-abl. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by both an abnormal expansion of the granuloblastic clone and the pathognomonic presence of the Philadelphia (Ph) chromosome that generates the BCR::ABL1 oncoprotein. Despite the surfacing of tyrosine kinase Inhibitors (TKIs) in 2001, which changed the evolution of the disease, resistance due to point mutation or compound alteration during treatment with target therapy may occur. One of the mutations that is still an on-going challenge in clinical and scientific field is the T315I mutation, since it gives patients a poor prognosis attributable to acquired resistance to therapy. In the following narrative review, we will discuss the current knowledge on the T315I mutation, explore the most suitable treatment options, examine the role of third-generation tyrosine kinase inhibitors, and outline potential future therapeutic strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myelogenous, Chronic, BCR-ABL PositiveFusion Proteins, bcr-ablMutationProto-Oncogene Proteins c-ablHumansProtein Kinase InhibitorsDrug Resistance, Neoplasm

Stichwörter der Autor:innen

BCR::ABL1CML mutationCML therapyT315I mutationacquired resistancechronic myeloid leukemiaprognosis

Substanzen

Protein Kinase InhibitorsFusion Proteins, bcr-ablBCR-ABL1 fusion protein, humanProto-Oncogene Proteins c-abl

Autor:innen und Institutionen

  • Division of Hematology, Department of Human Pathology in Adulthood and Childhood "Gaetano Barresi", University of Messina, Via Consolare Valeria, 98125 Messina, Italy.
  • Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy.
  • Department of General Surgery and Medical-Surgical Specialties, University of Catania, 95123 Catania, Italy.
  • IRCCS Bonino Pulejo Center, 98124 Messina, Italy.

ORCID-Profile: Manlio Fazio, Michele Massimino, Alessandro Allegra, Fabio Stagno

Zitieren

APA

Pierro, F., Stella, S., Fazio, M., Russo, S., Massimino, M., Mirabile, G., Belletti, D., Allegra, A., & Stagno, F. (2025). Chronic Myeloid Leukemia and the T315I BCR::ABL1 Mutation. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262311285

Vancouver

Pierro F, Stella S, Fazio M, Russo S, Massimino M, Mirabile G, et al. Chronic Myeloid Leukemia and the T315I BCR::ABL1 Mutation. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262311285

BibTeX
@article{Pierro2025,
  author = {Pierro, Federico and Stella, Stefania and Fazio, Manlio and Russo, Sabina and Massimino, Michele and Mirabile, Giuseppe and Belletti, Daniela and Allegra, Alessandro and Stagno, Fabio},
  title = {Chronic Myeloid Leukemia and the T315I BCR::ABL1 Mutation},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms262311285}
}
Kostenlos starten →